Riskin-Jones Hannah, Grogan Tristan, Kishan Amar, Raldow Ann
David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Department of Radiation Oncology, UCLA, Los Angeles, CA, USA.
Eur Urol Open Sci. 2020 Oct 10;21:69-76. doi: 10.1016/j.euros.2020.09.003. eCollection 2020 Oct.
Treatment for low-risk (LR), favorable intermediate-risk (FIR), and unfavorable intermediate-risk (UIR) prostate cancer (PC) is complicated by clinical equipoise between multiple options. It is unknown how prediagnosis health-related quality of life (HRQoL) and major depressive disorder (MDD) risk impact treatment decisions.
To analyze associations of patient-reported HRQoL and MDD risk with treatment for LR, FIR, and UIR PC patients.
Using the Surveillance, Epidemiology and End Results and Medicare Health Outcomes Survey-linked database, we identified 1678 PC patients (498 with LR, 685 with FIR, and 495 with UIR) aged ≥65 yr and diagnosed between 2004 and 2015, who completed the health outcomes survey ≤24 mo before diagnosis.
HRQoL was measured by physical (PCS) and mental (MCS) component summaries of the Medical Outcomes Study Short Form 36 (SF-36) and Veterans RAND 12-item (VR-12) health survey instruments. MDD risk was derived from survey items screening for depressive symptoms. Associations with treatment choice were assessed by multivariable multinomial logistic regression.
LR patients with higher PCS scores were more likely to receive radiation than surgery (adjusted odds ratio [AOR] 1.5 [95% confidence interval {CI}: 1.1-2.1; = 0.02]). FIR patients with MDD risk were more likely to receive neither treatment than surgery or radiation (surgery: AOR 2.6 [95% CI: 1.1-6.2; = 0.03]; radiation: AOR 2.2 [95% CI: 1.2-4.2; = 0.01]). UIR patients with MDD risk were more likely to undergo radiation than surgery (AOR 2.3 [95% CI: 1.0-4.9; =0.04]). Additionally, higher PCS scores were associated with receipt of surgery compared with neither treatment (AOR 1.5 [95% CI: 1.1-2.0; =0.01]). This study is limited by its retrospective design.
Older PC patients with MDD risk received less invasive treatments in the FIR and UIR groups. Higher PCS scores were associated with treatment modality in LR and UIR patients. HRQoL and MDD risk impact treatment choice, warranting additional study.
Treatment of prostate cancer requires thoughtful decision-making processes. This study shows that both pretreatment mental status and pretreatment physical status affect treatment decisions, and should be considered during counseling.
低风险(LR)、有利中风险(FIR)和不利中风险(UIR)前列腺癌(PC)的治疗因多种选择之间的临床平衡而变得复杂。尚不清楚诊断前的健康相关生活质量(HRQoL)和重度抑郁症(MDD)风险如何影响治疗决策。
分析患者报告的HRQoL和MDD风险与LR、FIR和UIR PC患者治疗之间的关联。
设计、设置和参与者:利用监测、流行病学和最终结果以及医疗保险健康结果调查链接数据库,我们确定了1678例年龄≥65岁且在2004年至2015年期间确诊的PC患者(498例LR患者、685例FIR患者和495例UIR患者),他们在诊断前≤24个月完成了健康结果调查。
HRQoL通过医学结果研究简表36(SF - 36)和退伍军人兰德12项(VR - 12)健康调查工具的身体(PCS)和心理(MCS)成分总结来测量。MDD风险来自筛查抑郁症状的调查项目。通过多变量多项逻辑回归评估与治疗选择的关联。
PCS评分较高的LR患者接受放疗而非手术的可能性更大(调整优势比[AOR] 1.5 [95%置信区间{CI}:1.1 - 2.1;P = 0.02])。有MDD风险的FIR患者不接受任何治疗的可能性比接受手术或放疗的可能性更大(手术:AOR 2.6 [95% CI:1.1 - 6.2;P = 0.03];放疗:AOR 2.2 [95% CI:1.2 - 4.2;P = 0.01])。有MDD风险的UIR患者接受放疗而非手术的可能性更大(AOR 2.3 [95% CI:1.0 - 4.9;P = 0.04])。此外,与不接受任何治疗相比,较高的PCS评分与接受手术相关(AOR 1.5 [95% CI:1.1 - 2.0;P = 0.01])。本研究受其回顾性设计限制。
FIR和UIR组中有MDD风险的老年PC患者接受侵入性较小的治疗。较高的PCS评分与LR和UIR患者的治疗方式相关。HRQoL和MDD风险影响治疗选择,值得进一步研究。
前列腺癌的治疗需要深思熟虑的决策过程。这项研究表明,治疗前的心理状态和身体状态都会影响治疗决策,在咨询过程中应予以考虑。